Lupin Receives US FDA Approval To Market For Penicillamine Tablets
Pharma major Lupin Limited has received approval from the United States Food and Drug Administration (FDA) to market for penicillamine tablets USP, 250 mg, a generic equivalent of Depen tablets, 250 mg, of Mylan Specialty, L.P.The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly.Penicillamine tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.Penicillamine tablets USP had an annual sales of approximately US$4 million in the US, according to IQVIA MAT September 2020.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
